• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012 Product Image

Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012

  • ID: 2233802
  • November 2012
  • 95 pages
  • Global Markets Direct

Skin And Skin Structure Infections (SSSI) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). Skin And Skin Structure Infections (SSSI) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Skin And Skin Structure Infections (SSSI) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 8
Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Skin And Skin Structure Infections (SSSI) Therapeutics – Products under Development by Companies 16
Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 17
GlaxoSmithKline plc 17
Rib-X Pharmaceuticals, Inc. 18
Paratek Pharmaceuticals, Inc. 19
Affinium Pharmaceuticals, Inc. 20
PolyMedix, Inc. 21
Nabriva Therapeutics AG 22
Cempra Pharmaceuticals, Inc. 23
Trius Therapeutics, Inc. 24
Tetraphase Pharmaceuticals Inc. 25
Durata Therapeutics Inc. 26
Skin And Skin Structure Infections (SSSI) – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
dalbavancin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GSK-1322322 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AFN-1252 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
omadacycline tosylate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PMX-30063 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BC-3781 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BC-7013 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
delafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
radezolid - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
radezolid - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
oritavancin disphosphate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fusidic acid - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
torezolid - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
faropenem medoxomil - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
JNJ-Q2 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ABI-0043 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
eravacycline - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 62
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 83
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 84
Skin And Skin Structure Infections (SSSI) – Product Development Milestones 85
Featured News & Press Releases 85
Oct 25, 2012: Durata Therapeutics Completes Target Enrollment In Phase III Study Comparing Dalbavancin To Vancomycin And Linezolid In ABSSSI Patients 85
Oct 19, 2012: Trius Presents Clinical Data On Antibiotic Drug Candidate Tedizolid At IDWeek 2012 85
Oct 18, 2012: Durata Therapeutics Presents Results From Skin Lesion Measurement Study Of Dalbavancin At IDWeek 2012 86
Oct 16, 2012: Trius Therapeutics To Present Data From Tedizolid Clinical Studies At IDWeek Conference 87
Oct 10, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Radezolid 87
Oct 04, 2012: Durata Therapeutics To Present Two Abstracts Concerning Dalbavancin At IDWeek 2012 88
Sep 17, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Delafloxacin 89
Sep 11, 2012: Durata Therapeutics Announces Completion Of QT Study Of Dalbavancin 90
Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 2012 90
Sep 11, 2012: PolyMedix Presents New Data On Defensin-Mimetic Antibiotics At 52nd Annual ICAAC 2012 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
GlaxoSmithKline plc, H2 2012 17
Rib-X Pharmaceuticals, Inc., H2 2012 18
Paratek Pharmaceuticals, Inc., H2 2012 19
Affinium Pharmaceuticals, Inc., H2 2012 20
PolyMedix, Inc., H2 2012 21
Nabriva Therapeutics AG, H2 2012 22
Cempra Pharmaceuticals, Inc., H2 2012 23
Trius Therapeutics, Inc., H2 2012 24
Tetraphase Pharmaceuticals Inc., H2 2012 25
Durata Therapeutics Inc., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 62
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 83
Skin And Skin Structure Infections (SSSI) Therapeutics – Dormant Products 84

List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos